Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

FDA Approves 2 New Biosimilars for Patients with Cancer

Web Exclusives - FDA Approvals, News & Updates

Retacrit First Biosimilar to Epogen/Procrit

On May 15, 2018, the FDA approved epoetin alfa-epbx (Retacrit; Pfizer) as the first biosimilar to epo­etin alfa (Epogen, Procrit; Amgen) for the treatment of anemia caused by chronic kidney disease, myelosuppressive chemotherapy, or the use of zidovudine in patients with HIV. The new biosimilar is also approved to reduce the need for allogeneic red blood cell transfusions in patients at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery.

“It is important for patients to have access to safe, effective and affordable biological products, and we are committed to facilitating the development and approval of biosimilar and interchangeable products,” said Leah Christl, PhD, Director of the Therapeutic Biologics and Biosimilars Staff in the FDA’s Center for Drug Evaluation and Research. “Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs.”

The approval of epoetin alfa-epbx was based on a review of evidence, including structural and functional characterization, and data regarding human pharmacokinetics and pharmacodynamics, clinical immunogenicity, animal studies, and clinical safety and efficacy demonstrating that epoetin alfa-epbx is a biosimilar to the reference drug. Epoetin alfa-­epbx is approved as a biosimilar, but is not an interchangeable drug.

Just as with the reference drug, epoetin alfa-epbx includes a boxed warning alerting healthcare providers and patients to the increased risks for death, heart problems, stroke, and tumor growth or recurrence. Additional warnings include hypertension, seizures, aplastic anemia, serious allergic reactions, and severe skin reactions.

Fulphila First Biosimilar to Neulasta

On June 4, 2018, the FDA approved pegfilgrastim-jmdb (Fulphila; Mylan GmbH) as the first biosimilar to pegfilgrastim (Neulasta; Amgen) to reduce the risk for neutropenia in patients who receive myelosuppressive chemotherapy known to be associated with febrile neutropenia.

“Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs and promote access,” said FDA Commissioner Scott Gottlieb, MD. “We’ll continue to prioritize reviews of these products to help ensure that biosimilar medications are brought to the market efficiently and through a process that makes certain that these new medicines meet the FDA’s rigorous standard for approval.”

The approval of pegfilgrastim-jmdb was based on a review of structural and functional characterization and clinical safety and efficacy related to pegfilgrastim-jmdb to demonstrate it is a biosimilar to the reference drug Neulasta.

Like all biosimilars, pegfilgrastim-jmdb is approved as a biosimilar but is not an interchangeable drug.

The most common adverse reactions with pegfilgrastim-jmdb are bone pain and pain in extremities. Patients who have had serious allergic reactions to human granulocyte colony-stimulating factors or filgrastim drugs should not take pegfilgrastim-jmdb.

Commenting on the approval of biosimilars by the FDA, Dr Gottlieb noted, “This summer, we’ll release a comprehensive new plan to advance new policy efforts that promote biosimilar product development. Biologics represent some of the most clinically important, but also costliest products that patients use to promote their health. We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from competition to existing biologics once lawful intellectual property has lapsed on these products.”

Related Items
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA News
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in FDA Approvals, News & Updates
Ivosidenib Now FDA-Approved as First-Line Treatment for AML with IDH1 Mutation
Web Exclusives published on May 7, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives published on April 16, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
Last modified: February 19, 2019